Clinical Trial Update: A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase III trial comparing QL1701 plus docetaxel to Herceptin plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• HERCEPTIN (trastuzumab)
• QL1701

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED